The Latest

  • An illustration for BioPharma Dive's deals database
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive

    Biotech’s M&A outlook is uncertain. Track the deals that are happening here.

    MannKind will pay about $300 million upfront to acquire scPharmaceuticals and its diuretic for chronic kidney disease and heart failure.

    Updated Aug. 25, 2025
  • A white sign with the word Lilly written in red stands outside of an office.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip

    Lilly says breast cancer drug extended survival in study

    Treatment with Verzenio helped people with a common type of early breast cancer liver longer than those given standard hormone therapy.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Amylyx drug comes up short; Sanofi names new CMO

    AMX0035 missed the goals of a study in progressive supranuclear palsy. Elsewhere, Novartis and BioArctic struck a deal, and Genentech started building its first East Coast factory.

  • An illustration of T cells attacking a cancer cell
    Image attribution tooltip
    Peddalanka Ramesh Babu via Getty Images
    Image attribution tooltip

    Startup Wugen raises $115M for ‘off-the-shelf’ CAR-T

    The St. Louis-based biotech hopes to submit an application for its leukemia and lymphoma therapy in 2027, if all goes well in an ongoing trial. 

  • A Regeneron sign in front of a building.
    Image attribution tooltip
    Courtesy of Regeneron Pharmaceuticals
    Image attribution tooltip

    RNA drug from Regeneron, Alnylam succeeds in rare autoimmune disease trial

    Cemdisiran helped control symptoms of generalized myasthenia gravis, but combination treatment with a Regeneron antibody didn't appear as effective.

    Updated Aug. 26, 2025
  • A thumbnail illustration for BioPharma Dive's IPO tracker
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive // Emerging biotech

    Biotech IPOs are the industry’s lifeblood. Track how they’re performing.

    Schizophrenia drug developer LB Pharmaceuticals on Friday filed plans for an initial public offering, after a six-month stretch with few substantive biotech offerings.

    Updated Aug. 25, 2025
  • A white sign with the word Lilly written in red stands outside of an office.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip
    Obesity drugs

    Lilly to submit obesity pill after hitting goal in third late-stage trial

    In people with diabetes and obesity, orforglipron led to weight loss near what people without diabetes experienced in prior testing.

  • Image of a brain in purple outline with red details.
    Image attribution tooltip
    Naeblys via Getty Images
    Image attribution tooltip

    AbbVie wagers more than $1B on Gilgamesh’s psychedelic drug

    The asset deal thrusts AbbVie to the forefront of the psychedelic field, handing it a therapy that recently scored positive Phase 2 results in major depression.

  • A photo of a sign showing the Food and Drug Administration logo
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip
    Vaccines

    FDA suspends license for Valneva’s chikungunya shot

    The agency said it had become aware of more reports of serious adverse events, leading center director Vinay Prasad to conclude the vaccine is no longer safe for its intended use.

    FDA
  • A double exposure photo illustration of a glass flask and a scientist holding a tube in a laboratory, with stock market information in the background.
    Image attribution tooltip
    MadamLead via Getty Images
    Image attribution tooltip

    Royalty Pharma buys BeOne stake in Amgen lung cancer drug sales

    An $885M deal with BeOne Medicine gives the pharma financier rights to a revenue stream from global sales of Imdelltra, which is sold by Amgen.

  • A stylized illustration of test tubes in front of a red line on a chart going up and to the right.
    Image attribution tooltip
    Adeline Kon/BioPharma Dive/BioPharma Dive
    Image attribution tooltip
    Deep Dive // Emerging biotech

    Biotech startups are built on venture capital. Track funding rounds here.

    MapLight Therapeutics' $372.5 million Series D round is the third-largest venture financing this year involving VC firms tracked by BioPharma Dive.

    Updated Aug. 7, 2025
  • man in a dark blue suit speaks in the oval office
    Image attribution tooltip
    Anna Moneymaker via Getty Images
    Image attribution tooltip

    FDA’s new accelerated pathway may open pharma up to risks, as well as benefits

    Faster review times could leave drugmakers vulnerable to litigation, while new Trump administration priorities add more uncertainty to the approval process.

    FDA
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    FDA cancels adcomm on Biohaven drug; Catalent lays off staff

    Analysts found the agency's decision to cancel the meeting encouraging. Elsewhere, the Novo Holdings-owned CDMO cut about 350 staff in Maryland.

  • A photo of Gilead's cell therapy manufacturing facility in Frederick, Maryland
    Image attribution tooltip
    Courtesy of Gilead
    Image attribution tooltip
    Emerging biotech

    Gilead dives into ‘in vivo’ cell therapy with $350M buyout of Interius

    The deal gives Gilead ownership of a technology that can genetically modify immune cells inside the body, an approach could that potentially widen access to CAR-T treatment.

  • The exterior of Ionis Pharmaceuticals' headquarters in Carlsbad, California.
    Image attribution tooltip
    Courtesy of Ionis Pharmaceuticals
    Image attribution tooltip

    FDA approves Ionis’ hereditary angioedema drug

    Dawnzera is the third medicine cleared by U.S. regulators this year for the rare genetic condition. Ionis set its list price at $57,462 per dose.

    Updated Aug. 21, 2025
  • A stylized illustration of a "patent thicket" for Jonathan Gardner's Nov. 1 story on Amgen's Enbrel.
    Image attribution tooltip
    Adeline Kon / BioPharma Dive/BioPharma Dive
    Image attribution tooltip
    Deep Dive // Patent thickets

    Drug patents protect pharma profits. Track when they’ll expire.

    This database now covers the 50 best-selling pharmaceutical products and has been updated to reflect current patent expiry expectations. 

    Updated April 9, 2025
  • U.S. President Donald Trump speaks during a joint press conference with European Commission President Ursula von der Leyen on July 27, 2025, in Turnberry, Scotland.
    Image attribution tooltip
    Andrew Harnik via Getty Images
    Image attribution tooltip

    US, EU agree to terms of framework trade pact

    The countries documented provisions of a deal that would set a 15% tariff on many EU imports, including cars, pharmaceuticals and semiconductors.

  • A Sarepta logo is displayed on a building in Cambridge, Massachusetts on Sept. 5, 2024.
    Image attribution tooltip
    Jacob Bell/BioPharma Dive
    Image attribution tooltip

    Sarepta pushes off debt payments in bid to regain financial footing

    A refinancing deal will delay the maturity of $700 million in debt until 2030, allowing the company to “fully fund” its pipeline and meet its near-term financial obligations, CEO Doug Ingram said. 

  • A photo of a declining stock price.
    Image attribution tooltip
    Leonid Sorokin via Getty Images
    Image attribution tooltip
    Biotech zombies

    Xoma, a drug royalty specialist, buys another ‘zombie’ biotech

    A deal to acquire Alkermes spinout Mural Oncology is Xoma’s fourth since June and the latest evidence of interest in buying and shutting down struggling drugmakers.

  • Eli Lilly company logo outside its Indiana headquarters
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip

    Lilly searching for new neuro chief as White set to retire

    Anne White, a 30-year company veteran who previously led the company’s oncology unit, will step down as head of Lilly Neuroscience at the end of December.

  • A person in a blue suit gestures while seated at a conference table.
    Image attribution tooltip
    Andrew Harnik via Getty Images
    Image attribution tooltip
    Trump administration

    The Trump administration is remaking HHS. Track the changes here.

    Susan Monarez’s confirmation by the Senate as CDC director ends uncertainty about authority at the agency, which has not had a formal acting head since the spring.

    Updated July 30, 2025
  • The logo of the Food and Drug Administration is seen in a close-up view of the agency's website.
    Image attribution tooltip
    Mario Guti via Getty Images
    Image attribution tooltip

    Rocket can resume gene therapy trial after FDA lifts hold

    The company plans to continue with a lower dose and a change in the pre-treatment regimen after a trial participant died earlier this year.

  • Robert F. Kennedy Jr. in a blue stripe suit points while speaking
    Image attribution tooltip
    Andrew Harnik via Getty Images
    Image attribution tooltip

    MAHA may take aim at pharma DTC ads

    RFK Jr. has his sights set on increasing oversight and enforcement against drugmakers that run afoul of advertising laws.

  • Two signs bearing the logo for CSL are seen outside of a corporate office
    Image attribution tooltip
    Asanka Ratnayake via Getty Images
    Image attribution tooltip

    CSL to separate vaccine business, cut jobs

    On an earnings call, CSL CEO Paul McKenzie described weakness in the U.S. market for seasonal flu vaccines as “disappointing” and “highly irrational.”

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip

    PTC drug for Friedrich’s ataxia rejected; Lilly sells nearly $7B in bonds

    The FDA said data for PTC's drug did not prove "substantial evidence of efficacy." Elsewhere, the FDA delayed its decision on a Regenxbio gene therapy and Skyhawk Therapeutics struck a deal.